CLINICAL_TRIALS
trial_result
· 2018-04-02
Clinical Trial Update: Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma [Phase 2]
Summary
Phase 2 trial of ponatinib in bevacizumab-refractory glioblastoma has completed and results were posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2018-04-02